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Abstract 
TGFβ1 was initially identified as a potent chemotactic cytokine to initiate inflammation, but 
the autoimmune phenotype seen in TGFβ1 knockout mice reversed the dogma of TGFβ1 
being a pro-inflammatory cytokine to predominantly an immune suppressor. The discovery of 
the role of TGFβ1 in Th17 cell activation once again revealed the pro-inflammatory effect of 
TGFβ1. We developed K5.TGFβ1 mice with latent human TGF1 overexpression targeted to 
epidermal keratinocytes by keratin 5. These transgenic mice developed significant skin in-
flammation. Further studies revealed that inflammation severity correlated with switching 
TGF1 transgene expression on and off, and genome wide expression profiling revealed 
striking similarities between K5.TGFβ1 skin and human psoriasis, a Th1/Th17-associated in-
flammatory skin disease. Our recent study reveals that treatments alleviating inflammatory 
skin phenotypes in this mouse model reduced Th17 cells, and antibodies against IL-17 also 
lessen the inflammatory phenotype. Examination of inflammatory cytokines/chemokines af-
fected by TGF1 revealed predominantly Th1-, Th17-related cytokines in K5.TGF1 skin. 
However, the finding that K5.TGF1 mice also express Th2-associated inflammatory cyto-
kines under certain pathological conditions raises the possibility that deregulated TGF sig-
naling is involved in more than one inflammatory disease. Furthermore, activation of both 
Th1/Th17 cells and regulatory T cells (Tregs) by TGFβ1 reversely regulated by IL-6 highlights 
the dual role of TGFβ1 in regulating inflammation, a dynamic, context and organ specific 
process. This review focuses on the role of TGFβ1 in inflammatory skin diseases. 
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Introduction 
Transforming growth factor β (TGFβ) is a mul-
tipotent cytokine consisting of TGFβ1, 2, and 3, with 
TGFβ1 being the most abundant isoform in most tis-
sues,  including  the  skin.  Smad2  and  Smad3  are 
phosphorylated once TGFβ binds to receptors I and II. 
Phosphorylated Smads bind with Smad4 to form het-
eromeric  complexes,  translocate  to  the  nucleus  and 
transcriptionally regulate TGFβ responsive genes [1]. 
TGFβ1 is secreted in a biologically latent form and be-
comes  activated  when  mature  TGFβ1  disassociates 
from its latency associated peptide dimer. TGFβ1 is a 
very potent stimulator of chemotaxis; TGFβ1 stimu-
lates  migration  of  monocytes,  lymphocytes,  neutro-
phils and fibroblasts with 10-15 M concentrations [2]. 
There are several animal models study the effects of 
TGFβ1. TGFβ1 knockout mice die from multifocal in-
flammation and autoimmune disorders in internal or-
gans, suggesting its immune suppressive effect in these 
organs  [3,  4].  However,  TGFβ1  knockout  mice  lack 
Langerhans  cells,  which  require  TGFβ1  for  develop-
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ment and activation, and therefore do not have skin 
inflammation  [5,  6].  Furthermore,  overexpression  of 
TGFβ1  in  the  epidermis  of  K5.TGFβ1  mice  (latent 
human TGF1 overexpression targeted to epidermal 
keratinocytes by keratin 5) results in significant skin 
inflammation  [7],  whereas  their  internal  organs  are 
protected  from  inflammation  and  autoimmune  dis-
eases by elevated systemic levels of TGFβ1 secreted 
by  K5.TGFβ1  keratinocytes  [8].  In  vitro  cultured 
keratinocytes isolated from these transgenic mice still 
exhibit  the  growth  inhibitory  effect  of  TGFβ1,  sug-
gesting that epidermal hyperplasia is mainly due to 
indirect  effects  of  TGFβ1-initiated  inflammation,  fi-
broblast hyperproliferation and angiogenesis [7]. The 
inflammatory effect of TGFβ1 on skin has been further 
confirmed  with  inducible  TGFβ1  transgenic  mice, 
where studies have shown inflammation is correlated 
with  TGFβ1  expression  [9,  10].  The  significance  of 
TGFβ1 overexpression mediating skin inflammation 
in our mouse model is further highlighted by a recent 
study showing that genome wide expression profiling 
in K5.TGF1 skin is strikingly similar to that in human 
psoriasis [11].  
IL-23/Th17 pathway is involved in TGFβ- 
mediated skin inflammation  
The role of T cells in the development of psoria-
sis was identified 20 years ago. Psoriasis was consid-
ered a Th1-associated autoimmune disease until the 
identification of Th17 cells [12-14]. Recent studies in-
dicate that Th17 cells and their upstream stimulator 
IL-23, or the IL-23/Th17 pathway, play crucial roles in 
the  pathogenesis  of  several  autoimmune  diseases 
such  as  rheumatoid  arthritis,  inflammatory  bowel 
disease and psoriasis [14-16]. Th17 cells differentiate 
from naïve T cells and are distinct from Th1 and Th2 
cells. Studies suggest TGFβ1 and IL-6 are required for 
mouse Th17 cell differentiation from  naïve CD4+ T 
cells [17-19]. In humans, the presence of TGF1 sig-
nificantly increases Th17 cell differentiation, although 
it is still an ongoing debate if TGF1 is absolutely re-
quired [12, 15, 20, 21]. 
IL-23  is  a  heterodimeric  cytokine  consisting  of 
IL-23p19 and IL-12p40 subunits. Many cell types, in-
cluding  monocytes/macrophages,  dendritic  cells,  T 
cells and keratinocytes, have been shown to express 
IL-23 [12, 22-24]. The IL-23 receptor (IL-23R) consists 
of the heterodimer that binds to the IL-23p19 subunit 
and  the  IL-23/IL-12p40  subunit.  IL-23R  has  been 
found on activated and memory T cell populations, 
but  not  naïve  T  cells  [25-27].  IL-6  and  TGFβ1  were 
shown to induce IL-23R expression. Although IL-23 
may  not  be  involved  in  the  differentiation  of  Th17 
cells  from  naïve  T  cells,  it  plays  a  key  role  in  the 
maintenance of Th17 cells, and promotes Th17 cells to 
be  more  terminally-differentiated  and 
pro-inflammatory [26]. Abnormal expression of IL-23 
has also been linked to the pathogenesis of autoim-
mune  inflammation.  Further  studies  showed  IL-23 
regulates its target genes through activation of STAT3 
[12, 27]. Based on current studies, Th17 cell differen-
tiation from naïve T cells requires TGFβ1 and IL-6, but 
full  and  sustained  differentiation  of  Th17  cells  also 
requires IL-23 and IL-1β [12, 21, 26]. Increased IL-23 
expression  has  been  found  in  psoriatic  skin  lesions 
[28,  29].  A  genomewide  association  study  (GWAS) 
also reveals an association between psoriasis and the 
IL-23  and  NF-κB  pathways  [30].  Furthermore,  anti-
bodies against the IL-23/IL-12 p40 subunit are effec-
tive treatments for human psoriasis patients [31-35]. 
These findings led to the hypothesis that IL-23 is in-
volved  in  human  psoriasis.  This  notion  is  further 
supported by experimental therapeutics showing ef-
ficacy  of  the  monoclonal  antibody  against  the 
IL-23p19 subunit to treat mice with xenografted hu-
man psoriasis lesions  [36]. Therefore, it is currently 
accepted that activation of Th17 cells, with or without 
Th1 cells, contributes to the pathogenesis of human 
psoriasis [37-41]. 
Several earlier reports indicated that TGFβ1 was 
abnormally expressed in human psoriasis [42-45]. In 
our  K5.TGFβ1  mice,  TGFβ1  causes  significant  skin 
inflammation recapitulating most features of human 
psoriasis: scaly and erythematous plaques in the skin 
grossly [7] and histologically epidermal hyperplasia, 
leukocyte infiltration in the dermis and/or in the up-
per  layer  of  the  epidermis  forming  subcorneal  mi-
croabscesses  (Fig.  1)  [7].  In  the  foot  pad  where  the 
thickness of the epidermis  is comparable to human 
skin,  rete  ridge  (down  growth  of  the  epidermis)  is 
obvious in K5.TGF1 skin (Fig. 1). The causal role of 
TGFβ1 in skin inflammation in mice was further con-
firmed  by  our  subsequent  study  using  a 
gene-switch-TGFβ1 mouse model [9]. In this mouse 
model,  temporal  TGFβ1  induction  resulted  in  skin 
inflammation, which abated when TGFβ1 induction 
was  halted  [9].  Based  on  the  K5.TGFβ1  transgenic 
mouse  model,  we  reported  that  molecular  mecha-
nisms underlying TGFβ1-induced skin inflammation 
could be attributed to Th1-type cytokines in the skin 
[7].  
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Fig.1. K5.TGFβ1 skin exhibits psoriasis-like histopathology. ① H&E staining of dorsal skin in normal wild type mouse (NL), which 
is significantly thinner than human epidermis. ② H&E staining of dorsal skin in K5.TGFβ1 transgenic mouse (Tg) showing epidermal 
hyperplasia, infiltrated leukocytes in the dermis and parakeratosis (arrow). ③ Subcorneal microabscesses (arrow) formed in the dorsal 
skin of K5.TGFβ1 transgenic mouse (Tg). ④ Foot pad skin from a normal wild type mouse (NL) showing epidermal thickness comparable 
with human epidermis. ⑤ Foot pad skin of a K5.TGFβ1 transgenic mouse (Tg) showing significant epidermal hyperplasia and downward 
growth of the epidermis forming rete ridge structures with infiltrated leukocytes between them; the characteristics are similar to human 
psoriatic lesions. 
 
It  has  been  shown  previously  that 
CD4+CD25+Foxp3+-regulatory  T  cells  (Tregs)  from 
patients  with  psoriasis  were  dysfunctional  in  sup-
pressing the proliferation of T responder cells [46] and 
over activation of the IL-23/Th17 pathway existed in 
human psoriasis [12]. TGF-β is critical for generation 
of both Tregs and Th17 cells from naïve T cells [17, 47] 
whereas the presence of IL-6 inhibits the conversion of 
T cells into Foxp3+ Tregs and favors Th17 immunity 
[48, 49]. The population of Tregs from lymph node 
cells  or  splenocytes  of  K5.TGFβ1  transgenic  mice 
showed no difference in comparison with that from 
wild type mice [50]. In vitro culture Tregs from both 
wild type and K5.TGFβ1 mice do not proliferate in 
response  to  polyclonal  stimulation  [50].  However, 
Tregs from K5.TGFβ1 transgenic mice failed to sup-
press T responder cell proliferation during later stages 
of disease development and the dysfunction of Tregs 
has  been  restored  in  K5.TGFβ1  mice  received 
8-methoxypsoralen  plus  ultraviolet  A  therapy 
(PUVA) with downregulation of IL-6 [50]. Those re-
sults suggested increased IL-6 in K5.TGFβ1 mice play 
a  crucial,  suppressive  role  in  TGFβ  induced  Tregs 
differentiation.  
To further investigate if the IL-23/Th17 axis is 
involved  in  TGFβ1  induced  skin  inflammation,  we 
studied  how  the  IL-23/Th17  pathway  is  altered  in 
K5.TGFβ1  mice.  Compared  to  wild  type  mice,  the 
numbers  of  IL-23p19  positive  keratinocytes  and 
stromal cells in the skin are significantly increased in 
K5.TGFβ1  [50].  Additionally,  high  levels  of  serum 
IL-17A,  IL-17F  and  IL-23  were  detected.  IL-23p19 
staining in dorsal skin and serum levels of IL-17 de-
clined  with  the  reduction  of  inflammation  after 
treatment with PUVA [50]. Further, platelet-activating 
factor (PAF), a potent biolipid mediator involved in 
psoriasis  pathogenesis,  also  induces  the  IL-23/Th17 
pathway;  blocking  PAF  by  its  receptor  antagonist 
results in a decrease of mRNA and/or protein levels 
of IL-17A, IL-17F, IL-23, IL-12A, and IL-6 in K5.TGF1 Int. J. Biol. Sci. 2012, 8 
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mice [51]. Increased numbers of Th17 cells were also 
found in Smad4-deleted oral mucosa where endoge-
nous TGF1 is overexpressed and signaling is mainly 
Smad3-dependent [52]. These results strongly indicate 
IL-23/Th17 axis involvement in TGFβ1 mediated in-
flammation. Supporting this finding, Mohammed et al 
recently reported that temporally and acutely induced 
TGFβ1  overexpression  in  premalignant  epidermal 
keratinocytes enhanced IL-17-producing cell popula-
tions  in  their  Tet-inducible  K5.TGFβ1  transgenic 
mouse  model  [10].  Further  analysis  in  their  study 
showed CD4+ and γδ+ T cells secreted IL-17A upon 
TGFβ1 induction [10]. Interestingly, TGFβ1 induction 
in  cultured  mouse  keratinocytes  pre-infected  with 
v-rasHA resulted in increased IL-23p19 and IL-6 tran-
scriptional expression dependent on autocrine TGFβ1 
signaling.  Conditioned  media  from  the  above  cul-
tured cells also caused IL-17A production in naïve T 
cells [10]. Therefore, it is likely that TGFβ1, through 
induction  of  inflammatory  cell-  and  keratino-
cyte-derived Th17-polarizing cytokines, contributes to 
the production of IL-17 in TGFβ1-induced inflamma-
tory skin tissue (Fig.2) [7, 10, 12, 50]. As IL-23 is pri-
marily involved in maintaining Th17 effector cells and 
does not function on naïve T cells  [26], using IL-23 
antibody alone is insufficient to antagonize constitu-
tive overexpression of TGFβ1-induced IL-17 produc-
tion and therefore shows no effect on TGF1-induced 
inflammation  (Fig.  2)  [53].  In  contrast,  directly  tar-
geting IL-17 with an IL-17 antibody treatment is ef-
fective  in  relieving  skin  inflammation  in  K5.TGFβ1 
mice (Fig.2) [50].  
Is TGFβ1 involved in Th2 cell mediated in-
flammatory skin diseases? 
All K5.TGFβ1 transgenic mice develop skin in-
flammatory  phenotypes  during  their  lifespan,  and 
visible  skin  inflammation  manifests  at  around 
2-months  of  age.  The  gross  phenotype  and  histo-
pathology largely mimics features of human psoriasis 
with dominant Th1 type cytokines in skin lesions [7]. 
However, a subsequent report shows that K5.TGF1 
mice also developed lesions and pathogenesis resem-
bling human atopic dermatitis (AD), with high IL-4 
expression and scattered eosinophils in lesional skin, 
and  high-serum  IgE  levels  [53].  There  are  several 
possibilities to reconcile these apparently paradoxical 
findings. First, Th1 and Th2 inflammatory skin dis-
orders are not always mutually exclusive. Skin barrier 
defects play an important role in AD [54]. Similarly, a 
GWAS  showed  that  gene  deletion  for  the  cornified 
envelope of the epidermis is linked to psoriasis sus-
ceptibility  [16].  Studies  have  shown  that  IL-17  pro-
duced by Th17 cells is also elevated in acute AD le-
sions, and the number of Th17 cells correlated with 
acute  AD  severity  [55,  56].  Psoriasis  and  late-phase 
AD  in  humans  share  many  pathologic  features  [38, 
57],  and  increased  TGFβ1  has  been  found  in  both 
psoriasis [42, 45] and AD [55]. Also, similar therapeu-
tic  approaches,  e.g.  corticosteroids,  cyclosporine  A 
and  phototherapy,  show  clinical  efficacy  for  both 
diseases  [57,  58].  This  clinical  evidence  reflects  an 
overlap  of  pathogenesis  occurring  in  vivo  between 
these  two  diseases.  Second,  TGFβ1  may  also  be  in-
volved  in  AD  pathogenesis.  TGFβ1  overexpression 
has been shown to cause infiltration of mast cells [7], 
which  favor  AD  development  [59,  60].  Third,  alt-
hough  psoriasis  and  AD  usually  have  distinct  Th1- 
and  Th2-associated  inflammatory  cytokines,  respec-
tively, Th2 and Th1 cytokine profile shifts have also 
been observed in both AD and psoriasis [38, 61-63]. 
The shift of cytokine profiles and pathological char-
acteristics could happen in K5.TGFβ1 mice at different 
ages or in housing conditions where they are exposed 
to  different  environmental  factors,  especially  under 
conditions  where  lesional  skin  barrier  functions  are 
severely compromised. For instance, the predominant 
Th2 cytokine profile found in one study [53] was not 
evident  in  other  studies  [50,  51]  or  in  mice  freshly 
re-derived in the SPF (Specific Pathogen Free) facility 
[7]. Lastly, TGF1-mediated skin  inflammation may 
be  involved  with  more  than  Th1/Th2  diseases,  as 
IL-17 antibody treatment or depletion of total T cells 
does  not  completely  eliminate  TGF1-induced  in-
flammation or infiltration of other leukocyte types [9, 
10, 50]. Therefore, the effects of TGFβ on immune cell 
regulation are complex, and formation of inflamma-
tion may be affected by other factors such as the en-
vironment. Long term and parallel evaluation of the 
phenotype  and  its  underlying  pathogenesis  in 
K5.TGF1  mice  will  advance  our  current  under-
standing of the role of TGFβ1 in the skin inflamma-
tion, and help design  new strategies for controlling 
human  inflammatory  disorders.  In  clinical  practice, 
treatments in psoriasis and AD are largely different, 
while some common methods are used for symptom 
controls. If TGF1 proves to be involved in the path-
ogenesis of both diseases, inhibition of TGF1 or its 
downstream effectors may be explored as therapeutic 
strategies. 
Experiments testing therapeutic approaches 
for TGFβ1-mediated skin inflammation in 
the K5.TGFβ1 mouse model 
K5.TGFβ1 transgenic mice develop a stable and 
significant  skin  inflammation  phenotype,  thus  this 
mouse model can be used for testing novel drugs and Int. J. Biol. Sci. 2012, 8 
 
http://www.biolsci.org 
232 
other strategies to control inflammatory diseases. For 
instance, we previously tested Enbrel, a psoriasis drug 
that inhibits the TNFα-NFκB pathway, in K5.TGF1 
mice and found that it alleviates the skin inflamma-
tory  phenotype  [9].  Additionally,  PUVA  has  been 
widely  used  as  an  alternative  therapeutic  approach 
for  human  psoriasis,  especially  for  severe  or  wide-
spread  psoriasis.  Our  recent  report  indicated 
K5.TGFβ1  mice  receiving  PUVA  treatment  had  sig-
nificantly  reduced  skin  inflammation  [50].  Further 
studies  on  the  underlying  mechanism  suggested 
PUVA therapy, in addition to its possible direct an-
ti-proliferative effects on keratinocytes [64], dramati-
cally  inhibited  the  IL-23/Th17  pathway  in 
TGFβ1-induced inflammation. By analyzing immune 
alterations in skin and serum in K5.TGFβ1 mice before 
and  after  PUVA  treatment,  we  found  that  several 
molecular components that lie upstream of Th17 ac-
tivation  signaling,  including  IL-23,  ROR-γt  and 
STAT3,  were  significantly  reduced  upon  PUVA 
treatment. Consequently, populations of IL-17A– and 
IL-17F–producing CD4+ T cells in pooled splenocytes 
were  decreased  ~2  and  ~6  fold,  and  IL-17A  with 
IL-17F cytokine expression in skin was significantly 
reduced. In addition, PUVA treatment has also been 
found to regulate the Th1/Th2 cell shift in K5.TGFβ1 
mice, characterized by inhibition of IFN-γ expression 
and induction of IL-10 in both serum and skin. Fur-
ther  studies  indicated  that  TGFβ1-induced  skin  in-
flammation  was  blocked  by  anti-IL-17  mAb.  These 
data verified the important role of the IL-23/Th17 axis 
in  TGFβ1-induced  skin  inflammation  and  further 
validated  this  mouse  model  for  testing  therapeutic 
approaches against skin inflammation. 
 
Fig.2. Schematic model depicts potential molecular mechanisms of IL23/Th17-mediated inflammation in K5.TGFβ1 
skin. A. TGFβ1 is overexpressed in the epidermis of K5.TGFβ1 mice and released into, and activated in the dermis, where it attracts 
inflammatory cells. Inflammatory cells in cooperation with keratinocytes produce IL-23, IL-1β, IL-6 and other cytokines or chemokines in 
stroma. B. Th17 cells develop from naïve T cells in the presence of TGFβ1 and IL-6. IL-23, together with IL-1β act on activated/memory 
T cells to maintain Th17 cell activation. Anti-IL-23 antibody treatment on K5.TGFβ1 mice partially inhibits Th17 cell producing IL-17, but 
not enough to block TGFβ1-induced Th17 cell proliferation. Direct targeting IL-17 with anti-IL17 treatment has a more potent effect on 
relieving skin inflammation in K5.TGFβ1 mice. Int. J. Biol. Sci. 2012, 8 
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Future perspectives  
Our K5.TGFβ1 transgenic mice provide a useful 
model in exploring the function of TGFβ1 in the for-
mation of skin inflammation. To further understand 
which inflammatory skin diseases in humans involve 
TGFβ1-induced  skin  inflammation,  levels  of  TGFβ1 
and  its  signaling  components  in  human  diseases 
should be carefully examined. Unbiased cross-species 
comparisons of the pathological and molecular alter-
ations between human diseases and K5.TGF1 mice 
should  be  performed.  Similar  to  the  study  using 
whole-genome  transcriptional  profiling  [11], 
high-throughput  proteomics  approaches  using 
K5.TGFβ1 skin at different disease stages and samples 
from  human  inflammatory  skin  diseases  could  also 
provide  important  molecular  biomarkers  of 
TGFβ-mediated  inflammation.  These  experiments 
will help us delineate differences and similarities in 
the pathogenesis between TGFβ1 transgenic mice and 
human inflammatory skin diseases. 
Moreover, this mouse model will allow us to test 
various therapeutic strategies for controlling inflam-
matory skin diseases. Because the experimental ther-
apeutic approaches explored in K5.TGF1 mice can-
not  completely  or  permanently  reverse 
TGFβ1-induced  skin  inflammation,  direct  inhibition 
of TGFβ1 in the skin should be explored as a thera-
peutic strategy for inflammatory skin diseases where 
TGF1 overexpression plays a causal role in disease 
pathogenesis.  
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